/
Oncology
Castration-Resistant Prostate Cancer
10
Pipeline Programs↗
7
Active Trials↗
11
Companies Involved↗
Castration-resistant Prostate Cancer is an early-stage landscape with 10 programs across 11 companies. The most active players are Convergent Therapeutics, Sichuan Baili Pharmaceutical Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 1
No programs
Phase 27
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
83%
Small molecule
5 of 6 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 100% of 10 pipeline programs.
Analysis
Trial Status
7
clinical trials
Recruiting4 · 57%
Active, not recruiting2 · 29%
Not yet recruiting1 · 14%
Clinical Trials
Trial Activity
7 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)